About Cellauto
关于赛动智造
Innovative Technology
Founded in 2017, Shenzhen CellAuto Technology Co., Ltd. is the developer of the National Engineering Research Center for Key Generic Technologies of the Cell Industry. We are committed to advancing automation, digitalization, and intelligent manufacturing technologies, delivering end-to-end intelligent manufacturing solutions for innovative industries such as cell and gene therapy (CGT) and radiopharmaceuticals. Supported by a multidisciplinary R&D team with expertise in Biotechnology (BT), Information Technology (IT), and Automation Technology (AT), CellAuto is a National High-Tech Enterprise and a pioneer in the development and large-scale production of digital intelligent manufacturing lines for biopharmaceuticals in China. We are also the only domestic company with independent R&D and mass-production capabilities for fully automated radiopharmaceutical dispensing systems. Our solutions have been adopted by numerous leading institutions, helping customers increase production efficiency by more than 70% while strengthening regulatory compliance and ensuring consistent product quality.
Intellectual Property
CellAuto has built a strong intellectual property portfolio, with 209 patent applications, including: 98 invention patents; 90 utility model patents; 1 PCT international patent; 2 design patents; 7 software copyrights.The company has also led the development of: 4 national industrial innovation platforms; 1 Guangdong Provincial Key R&D Project; 1 Shenzhen Major Science and Technology Project; 1 Shenzhen Biomedical Industry Public Service Platform.
Global Strategic Vision
CellAuto is committed to accelerating the transformation of China's biopharmaceutical industry from manual operations to automated, intelligent, and digital manufacturing. Our mission is to reduce occupational exposure risks while ensuring manufacturing safety, regulatory compliance, and consistent product quality.
Since its founding, the company has established a comprehensive intelligent technology innovation system, providing compliant, efficient, and sustainable manufacturing solutions that support the long-term development of the global biopharmaceutical ecosystem. As an early pioneer in the clinical translation of biopharmaceuticals, a national leader in radiopharmaceutical manufacturing, and a trusted provider of intelligent pharmaceutical manufacturing solutions, CellAuto delivers complete implementation and turnkey delivery of digital, intelligent, and automated production lines across these advanced therapeutic fields.
History and Development
发展里程碑
- Co-established an intelligent, automated CDMO platform for cell therapeutics with Fujian Maternity and Child Health Hospital.
- Partnered with Qionghai Beike to establish an Advanced Intelligent Manufacturing Demonstration Base in Lecheng, Hainan, supporting localized point-of-care manufacturing.
- Awarded the Key Special Project for High-end Medical Devices under the Guangdong Provincial Key R&D Program.
- Achieved ISO 9001 Quality Management System Certification.
- Co-established an automated virology laboratory with the Chinese Center for Disease Control and Prevention (CDC).
- Co-founded an Orthopedic Clinical Translation Center with Shenzhen Pingle Orthopedic Hospital.
- Co-established the Joint Laboratory for Clinical Translation of Cell Therapy with Qianhai Shekou Free Trade Zone Hospital.
- Awarded the Key Special Project for Stem Cell Research and Organ Repair under the National Key R&D Program of the Ministry of Science and Technology.
- Undertook the national industrialization project Integrated Application Engineering of Biotechnology and Information Technology.
- Awarded a major special project by the Ministry of Industry and Information Technology (MIIT).
- Led the development of the Shenzhen Major Industrial Public Service Platform.
- Following the release of the updated NMPA GMP Guidelines for Cell Products, launched the AI-powered CellAuto Matrix, enabling fully enclosed, continuous, and automated cell manufacturing.
- Participated in the press conference for China's 14th Five-Year Plan for Bioeconomy Development.
- Commercialized core technology modules and delivered China's first fully automated radiopharmaceutical dispensing system.
- Recognized as a National High-Tech Enterprise.
- Delivered the world's first fully automated intelligent cell manufacturing system with independent mesenchymal stem cell (MSC) production capability.
- Selected as a 2021 Future Unicorn Enterprise.
- Initiated the planning and construction of the National Engineering Research Center for Key Generic Technologies of the Cell Industry.
- Received the Second Prize of the National Technological Invention Award.
- The United States released the Roadmap for Cell Manufacturing to 2030, highlighting the global importance of intelligent cell manufacturing.
- Introduced the world's first prototype of a fully automated intelligent cell manufacturing system, capable of end-to-end autonomous MSC processing.
- Established an R&D laboratory dedicated to fully automated intelligent cell manufacturing. Built an interdisciplinary AT + BT + IT R&D team, laying the foundation for the company's core technology platform.